Overview Anti-infectives: Recent advances in the treatment of septic shock

References

• ACCP/SCCM Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine (1992) 20: 864–874.
   Google Scholar
• Consensus definitions of terms applied to patients in varying stages of sepsis. Also details physiological variables, methods of severity scoring and guidelines for innovative therapies, such that clinical trials can be more effectively compared.
   Google Scholar
• EDWARDS JD: Management of septic shock. BMJ (1993) 306: 1661–1664.
   PubMed Web of Science ®Google Scholar
• BONE RC, SPRUNG CL, SIBBALD WJ: Definitions for sepsisand organ failure. Critical Care Medicine (1992) 20: 724–726.
   PubMed Web of Science ®Google Scholar
• CORRIVEAU CC, DANNER RL: Endotoxin as a therapeutic target in septic shock. Infectious Agents and Disease (1993) 2: 35–43.
   PubMedGoogle Scholar
• Review of the role of endotoxin in septic shock and current knowledge of the biological actions of LPS. Questions the value of anti-endotoxin stratagies, though is followed by reference 18 herein, reviewing this form of therapy.
   Google Scholar
• GIROIR BP: Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cas-cade. Critical Care Medicine (1993) 21: 780–789.
   PubMedGoogle Scholar
• Describes current stratagies in therapy of septic shock, concentrating on the role of TNF and IL-1.
   Google Scholar
• ZEIGLER EJ, MCCUTCHAN JA, FLEREN J, GLAUSER MP, SADOFF JC, DOUGLAS IT, BRAUDE Al: Treatment of Gram-negative bacteremia and shock with human an-tiserum to a mutant Escherichia coll. New Eng. J. Med. (1982) 307: 1225–1230.
   PubMed Web of Science ®Google Scholar
• Intravenous Immunoglobulin Collaborative Study Group: Prophylactic intravenous administration of standard Immune globulin as compared with core-lipopolysac-charide immune globulin in patients at high risk of post-surgical infection. New Eng. J. Medi. (1992) 327: 234–240.
   PubMedGoogle Scholar
• Large-scale clinical study of use of immunoglobulin and core-LPS hyper itrununoglobulin in infection. Concluded that immunoglobulin was effective but core-LPS globulin was not and raises questions regarding how anti-LPS antibodies act.
   Google Scholar
• SALADINO MD, BALDWIN G, ALPERT G, PARSONNET J, GILLIS Z, THOMPSON C, SIBER G, FLEISHER G: Effect of a human inamunoglobulin preparation for intravenous use in a rabbit model of meningococcal endotoxin-in-duced shock. Critical Care Medicine (1992) 20: 816–822.
   PubMedGoogle Scholar
• SCHEDEL I, DREIKHAUSEN U, NENTWIG B, HOCK-ENSCHNIEDER M, RAUTHMANN D, BALIKCIOGLU S, COLDEWEY R, DEICHER H: Treatment of Gram-negative septic shock with an inamunoglobulin preparation: a prospective, randomised clinical trial Critical Care Medicine (1991) 19:1104–1113.
   Google Scholar
• ZIEGLER EJ, FISHER CJ, SPRUNG CL, STRAUBE RC, SADOFF MD, FOULKE GE, WORTEL CH, FINK MP, DELLINGER RP, TENG NH, ALLEN IA, BERGER HJ, KNATTERUD LOBUGLIO AF, SMITH CR: Treatment of Gram-negative bactereffuia and septic shock with II4-1A human mono-clonal antibody against endotoxin. New Eng. J. Med. (1991) 324: 429–436.
   PubMed Web of Science ®Google Scholar
• Phase III clinical trial of HA-1A monoclonal antibody in septic shock. Concluded that HA-1A was effective in the proportion of patients (37 %) subsequently shown to have Gram-negative bacteraemia.
   Google Scholar
• GREENMAN RE, SCHEIN RMH, MARTIN MA, WENZEL RP, MacINTYRE NR, EMMANUEL G, CHMEL H, KOHLER RB, McCARTHY M, PLOUFFE J, RUSSEL1 JA: A controlled clini-cal trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. Journal of the American Medical Association (1991) 266: 1097–1102.
   Google Scholar
• Use of Xomen E5 monoclonal antibody in clinical trial with similar conclusion to that of reference 10, though neither trial was sub-sequently accepted by the FDA as proof of efficacy.
   Google Scholar
• FOOD AND DRUG ADMINISTRATION: Transcript of open meeting. Vaccines and Related Biological Products (1991) 1: 1–270.
   Google Scholar
• LUCE JM: Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Critical Care Medicine (1993) 21: 1233–1241.
   PubMed Web of Science ®Google Scholar
• Describes the history of HA-1A, and briefly of E5, anti-endotoxin antibodies, including cost-effectiveness analysis. Concludes against clinical use of the drug but predicts some pitfalls which could be avoided for other new technologies.
   Google Scholar
• Sepsis/Septic shock therapeutics. Drug & Market Devel-opment (1992) 2: 184–191.
   Google Scholar
• DAVIS J: New approaches to septic shock. Scrip World Pharmaceutical News (1993) 1793: 22–23.
   Google Scholar
• RAFF HV, DE'VEREUX D, SHUFORD W, ABBOTT-BROWND, MALONEY G: Human monoclonal antibody with protective activity for Escerichia colt K1 and Neisserta meningitidis group B infections. J. Inject. Dis. (1988) 157: 118–126.
   PubMedGoogle Scholar
• MARRA M, THORNTON MB, SNABLE JL, WILDE CG, SCOTT RW: Endotoxiffbinding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Critical Care Medicine (1994) 22: 559–565.
   PubMed Web of Science ®Google Scholar
• CORRIVEAU CC, DANNER RL: Anti-endotoxin therapies for septic shock. Infectious Agents and Disease (1993) 2: 44–52.
   PubMedGoogle Scholar
• QUEZADO ZMN, HOFFMAN WD, BANKS SM, ALLING DW, KOEV CA, DANNER RL, ELIN RJ, HOSSEINI JM, BACHER JD, PARKER TS, LEVINE DM, RUBIN AL, NATANSON C: Thera-peutic trial of reconstituted human high density lipo-protein in a dog model of Gram-negative septic shock: preliminary results. Critical Care Medicine (1993) 21(suppl): S227.
   Google Scholar
• KITCHENS RL, ULEVITCH RJ, MUNFORD RS: Lipopolysac-charide (LPS) partial structures inhibit responses to LPS In a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. J. Exp. Med. (1992) 176: 485–494.
   PubMed Web of Science ®Google Scholar
• LYNN WA: Prospects for the Immunotherapy of septic shock. Cum. Opin. Invest. Drugs (1993) 2: 973–981. Review of stratagies for treatment of septic shock, concentrating on approaches blocking LPS action but briefly covering many areas with therapeutic potential.
   Google Scholar
• MANTHEY CL, Perera PY, QURESHI N, STL'TZ PL, HAMIL-TON TA, VOGEL SN: Modulation of lipopolysaccharide-induced macrophage gene expression by Rbodobacter sphaeroides lipid A and SDZ 880.431. Infection and Immunity (1993) 61: 3518–3526.
   Google Scholar
• WRIGHT SD, RAMOS RA, TOBIAS PS, ULEVITCH RJ, MATHISON JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Sci-ence (1990) 249: 1431–1433.
   PubMed Web of Science ®Google Scholar
• GLAUSER MP, ZANETTI G, BAUMGARTNER J-D, COHEN J Septic shock: pathogenesis. Lancet (1991) 338: 732–735
   PubMed Web of Science ®Google Scholar
• HURLEY J.O . : Reappraisal of the role of endotoxin in thesepsis syndrome. Lancet (1993) 341: 1133–1135.
   PubMed Web of Science ®Google Scholar
• CUNNION RE: Clinical trials of Immunotherapy for sepsis. Critical Care Medicine (1992) 20: 721–722.
   PubMedGoogle Scholar
• ICHAITOV RM, PINEGIN BV, BUTAKOV AA, ANDRONOVA TM: Immunotherapy of infectious post-operative com-plications with glucosaminyImuramyl dipeptide (GMDP) In: Immunotherapy of Infections (1994) MASH-11101 (Ed.), Marcel Dekker, in press.
   Google Scholar
• Clinical trial results of prophylactic use of an immunostimulant to treat post-operative septic complications.
   Google Scholar
• EVANS S, KING DP: Cytokines in acute illness. Care of the Critically 11/ (1993) 9: 261–265.
   Google Scholar
• GUSTAFSON GL, RHODES MJ: A rationale for the prophy-lactic use of monophosphoryl lipid A in sepsis and septic shock. Biochem. Biopbys. Res. Comm. (1992) 182: 269–275.
   PubMedGoogle Scholar
• HENDERSON B, BLAKE S: Therapeutic potential of cytokame manipulation. TiPS (1992)13: 145–152.
   PubMed Web of Science ®Google Scholar
• Broad review of current understanding of cytokine production, and actions, and possibilities for manipulation in various pathophysi-ological states.
   Google Scholar
• BELLOMO R, TIPPING P, BOYCE N: Continuous veno-ve-nous he.mofiltration with dialysis removes cytokines from the circulation of septic patients. Critical Care Medicine (1993) 21: 522–526.
   Google Scholar
• WAAGE A, AASON AO: Different role of cytokine media-tors in septic shock related to meningococcal disease and surgery/polytrauma. Immunological Reviews (1992) 127: 221–230.
   PubMed Web of Science ®Google Scholar
• STEVENS D, BRYANT AE, HACKETT SP: Sepsis syndromes and toxic shock syndromes: concepts in pathogenesis and a perspective of future treatment stratagies. cum. opin. Infect. Dis. (1993) 6: 374–383.
   Google Scholar
• Review of various cytokines involved in septic shock and how they interact. Concentrates on anti-TNF and anti-IL-1 stratagies in consid-ering possible therapies.
   Google Scholar
• TRACEY KJ, FONG Y, HESSE DG, MANOGUE KR, LEE AT, KUO GC, LOWRY SF, CERAMI A: Anti-cachectin/TNF antibodies prevent septic shock during lethal bactere-mia. Nature (1987) 330: 662–664.
   PubMed Web of Science ®Google Scholar
• WENZEL R: New hope for anti-TNF MAb in sepsis. Scrip World Pharmaceutical News (1993) 1868: 29.
   Google Scholar
• LOETSCHER H, PAN YE, LAHM H-W, GENTZ R, BROCK-HAUS M, TABUCHI H, LESSLAUER W: Molecular dotting and expression of the human 55 kd tumor necrosis factor receptor. Cell (1990) 61: 351–359.
   PubMed Web of Science ®Google Scholar
• KOHNO T, BREWER MT, BAKER SL, SCHWARTZ PE, KING MW, HALE KK, SQUIRES CH, THOMPSON RC, VANNICE JL: A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor Inhibitor. Proc. Nat. Acad. Sci., USA (1990) 87: 8331–8335.
   PubMed Web of Science ®Google Scholar
• SCHALL TJ, LEWIS M, KOLLER KJ, LEE A, RICE GC, WONG GHW, GATANAGA T, GRANGER GA, LENTZ R, RAAB H, KOHR WJ, GOEDDEL DV: Molecular cloning and expres-sion of a receptor for human tumor necrosis factor. Cell (1990) 61: 361–370.
   PubMed Web of Science ®Google Scholar
• Three related papers describing the cloning and expression of the two types of TNF receptors. The papers demonstrate that the extracellular portions of the receptors can act as naturally occuring inhibitors of TNF actions and by molecular cloning the extracellular sections can be selectively expressed and used as soluble TNF binding proteins.
   Google Scholar
• EDGINGTON SM: Molecular crosstalk: will virology and growth-factor research aid cytokine drug discovery? Bio/technology (1993) 11: 465–470.
   PubMedGoogle Scholar
• Interesting speculative article about how an understanding of viral defence responses through immune modulation helps in predicting cytokine actions and receptor-mediated signalling.
   Google Scholar
• DINARELLO CA: Modalities for reducing interleukin 1 activity in disease. Immunology Today (1993) 14: 260–264. Describes IL-1 actions and current modalities for manipulating deleterious biological effects.
   Google Scholar
• AIURA K, GELFAND JA, BURKE JF, THOMPSON RC, DI-NARELLO CA: Interieukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypo-tension and reduces circulating levels of tumor necrosis factor and IL-1 in rabbits. Infection and Immunity (1993) 61: 3342–3350.
   PubMed Web of Science ®Google Scholar
• FISHER C, SLOTMAN GJ, OPAL SM, PRRIBLE JP, BONE RC, EMMANUEL G, NG D, BLOEDOW DC, CATALANO MA: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syn-drome: a randomised, open-label, placebo-controlled multicenter triaL Critical Care Medicine (1994) 22: 12–21.
   Google Scholar
• SPALDING BJ: In shocking synergen, sepsis tallies third victim. Rio/technology (1993) 11: 428–429.
   Google Scholar
• Stover Haley Noyes Life Science Advisory Group: Affymax Drug discovery Programs. Affymax Company Prospectus (1992) p15.
   Google Scholar
• SPRIGGS MK, HRUBY DE, MALISZEWSKI CR, PICKUO DJ, SIMS JE, BULLER ML, VANSLYKE J: Vaccinia and cowpox viruses encode a novel secreted interleukin-1 binding protein. Cell (1992) 71: 145–152.
   PubMed Web of Science ®Google Scholar
• ALCAMI A, SMITH GL: A soluble receptor for interleukin-1 encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell (1992) 71: 153–167.
   PubMed Web of Science ®Google Scholar
• KREFT AF, SCHEISER GA, SKOTNICKI JS: Anti-inflaffunatory patent highlights from the second half of 1992. Curr.Opin. Tber. Patents (1993) 3: 513–543.
   Google Scholar
• Preceeding article covering new patents in all areas of chronic inflammatory disease. Includes sections on leukotriene inhibitors and receptor antagonists
   Google Scholar
• FIORENTINO DF, ZLOTNIK A, MOSMANN TR, HOWARD M, O'GARRA A: IL-10 inhibits cytokine production by acti-vated macrophages. J. Immunol. (1991) 147: 3815–3822.
   PubMed Web of Science ®Google Scholar
• MOORE K, O'GARRA A, MALEFYT R DE W, VIEIRA P, MOSMANN TR: Interleukin 10. Ann. Rev. Immunol. (1993) 11: 165–190.
   PubMedGoogle Scholar
• FENTON MJ, BURAS JA, DONNELLY RP: IL-4 reciprocallyregulates IL-1 and IL-1 receptor antagonist expression In human monocytes. Immunol. (1992) 149: 1283–1288.
   Google Scholar
• MINTY A, CHALON P, DEROCQ J-M, DUMONT X, GUILLEMOT J-C, KAGHAD M, LABIT C, LEPLATOIS P, LIAUZUN P, MILOUX B, MINTY C, CASELLAS P, LOISON G, LUPKER J, SHIRE D, FERRARA P, CAPUT D: Interleulcin–13
   Google Scholar
• Is a new human lymphokine regulating inflammatory and immune responses. Nature (1993) 362: 248–250. Directed research to find novel cytokine with regulatory activity. Used molecular cloning techniques to identify cDNA sequence and express the protein for IL-13 which acts in a similar way to IL-4 and IL-10 in inhibiting inflammatory cytokines.
   Google Scholar
• OSWALD IP, GAZZINELLI RT, SHER A, JAMES SL: IL-10 synergizes with IL-4 and transforming growth factor-0 to inhibit macrophage cytotoxic activity. J. Immunol. (1992) 148: 3578–3582.
   PubMed Web of Science ®Google Scholar
• MAYER RJ, MARSHALL LA: New insights on mammalian phosphlipase Az: comparison of arachidonyl-selective and -nonselective enzymes. FASEB Journal (1993) 7: 339–348.
   PubMed Web of Science ®Google Scholar
• Describes current knowledge of the role of the different forms of phospholipases A2. Also reviews pharmacological manipulation although concentrates on the 14 kD form where more is known but which may be the less important form in septic shock.
   Google Scholar
• PRUZANSKI W, SHERMAN ML, KUFE DW, VADAS P: Induc-tion of circulating phospholipase A2 by intravenous administration of recombinant human tumour ne-crosis factor. Mediators of Inflammation (1992) 1: 235–240.
   PubMedGoogle Scholar
• FINK MP: Phospholipases Az: potential mediators of the systemic inflammatory response syndrome and the multiple organ dysfunction syndrome. Critical Care Medicine (1993) 21: 957–959.
   PubMedGoogle Scholar
• MITCHELL J, AKARASEREENONT P, THIEMERMANN C, FLOWER RJ, VANE JR: Selectivity of nonsteroidal antiin-flammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Nat. Acad. Sci., USA (1993) 90: 11693–11697.
   PubMed Web of Science ®Google Scholar
• LEMAHIEU RA, CARSON M, HAN R, MADISON,V.S., HOPE WC, cHEN T, MORGAN DW, HENDRICKSON HS: N-(Car-boxymethy1)-N-[3,5-bis(decyloxy)-phenyl] glycine (Ro 23–9358): a potent inhibitor of secretory phospholipase A2 with anti-inflammatory activity. J. Med. Chem. (1993) 36: 3029–3031.
   Google Scholar
• BEATON H, BENNION C, CONNOLLY AR, GENSMANTELNP, HALLAM C, HARDY K, HITCHIN B, JACKSON CG, ROBINSON DH: Discovery of new non-phospholipid Inhibitors of the secretory phospholipases A2. J. Med. Chem. (1994) 37: 557–559.
   PubMed Web of Science ®Google Scholar
• REGOLI D, RHALEB N-E, DION S, DRAPEAU G: New selective bradykinin antagonists and bradykinin B2 receptor characterization. TiPS (1990)11: 156–161,
   PubMedGoogle Scholar
• WIRTH K, HOCK FJ, ALBUS U, LINZ W, ALPERMANN HG, ANAGNOSTOPOULOS H, HENICE S, BREIPOHL G, KNOLLE J, SCHOLKENS BA: Hoe 140 a new potent and long acting bradykinin antagonist: in vivo studies. British Journal of Pharmacology (1991) 102: 774–777.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTY S, WILKINS D, KYLE DJ: Design of potent, cyclic peptide bradykinin antagonists from conforma-tionally constrained linear peptides. J. Med. Chem. (1993) 36: 2569–2571.
   PubMedGoogle Scholar
• SALVINO JM, SEAONE PR, DOUTY BD, AWAD MA, DOLLE RE, HOUCK WT, FAUNCE DM, SAWUTZ DG: Design of potent non-peptide competitive antagonists of the hu-man bradykinin B2 receptor. J. Med. Chem. (1993) 36: 2583–2584.
   PubMedGoogle Scholar
• Intensive research has previously identified peptide antagonists of bradykinin receptors but this is the first report of a study to find novel non-peptide agents.
   Google Scholar
• KYLE D, CHAKRAVARTY S, SINSKO JA, STORMANN TM: A proposed model of bradykinin bound to the rat 82 receptor and its utility for drug design. J. Med. Chem. (1994) 37: 1347–1354.
   PubMedGoogle Scholar
• CHU M, PATEL MG, GULLO VP, TRUUMEES I, PUAR MS,MCPHAIL AT: Sch-47918: a novel PAF antagonist from the fungus Phoma species. J. Org. Chem. (1992) 57: 5817–5818,
   Web of Science ®Google Scholar
• BONE RC: Phospholipids and their inhibitors: a criticalevaluation of their role in the treatment of sepsis. Critical Care Medicine (1992) 20: 884–890.
   PubMedGoogle Scholar
• BONE RC: Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of sepsis. Critical Care Medicine (1992) 20: 891–898.
   PubMedGoogle Scholar
• HUGHES S: Cell adhesion molecules: the key to a universa! panacea? Scrip Magazine (1993) 15: 30–33. Cell adhesion molecules are prime targets for novel drug discovery. This article reviews the pharmaceutical research being carried out to manipulate them in pathological situations.
   Google Scholar
• McCALL T, VALIANCE P: Nitric oxide takes centre-stage with newly defined roles. TiPS (1992) 13: 1–6.
   PubMed Web of Science ®Google Scholar
• GREEN SJ, NACY CA: Antimicrobial and immunopathologic effects of cytokine-induced nitric oxide synthesis. Curr. Opin. Infect. Dis. (1993) 6: 384–396. Review of a rapidly expanding field of research concentrating on cytokine-induced nitric oxide synthesis and its regulation.
   Google Scholar
• VANE J, MITCHELL JA, APPLETON I, TOMLINSON A, BISHOP-BAILEY D, CROXTALL J, 'WILLOUGHBY DA: In-ducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc. Natl. Acad. Sci., USA (1994) 91: 2046–2050.
   PubMed Web of Science ®Google Scholar
• RIVEROS-MORENO V, BEDDELL C, MONCADA S: Nitric oxide synthase: structural studies using anti-peptide antibodies. Eur.J. Biochem. (1993) 215: 801–808.
   PubMedGoogle Scholar
• OLKEN NM, MARLETTA MA: NG-ally1 and NG-cyclopropyl-L-arghaine: two novel inhibitors of macrophage nitric oxide synthase. J. Med. Chem. (1992) 35: 1137–1144.
   PubMed Web of Science ®Google Scholar
• PETROS A, BENNETT D, VALLANCE P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock Lancet (1991) 338: 1557–1558,
   Google Scholar
• LOREN-FE JA, LANDIN L, PABLO R, RENES E, LISTE D: L-Arginine pathway in the sepsis syndrome. Critical Care Medicine (1993) 21: 1287–1295.
   PubMedGoogle Scholar
• COBB JP, CUNNION RE, DANNER RL: Nitric oxide as a target for therapy in septic shock. Critical Care Medicine (1993) 21: 1261–1263.
   PubMedGoogle Scholar
• STEINER J, GRINDLEY J: Phase III dinicals - trials and tribulations. Scrip Magazine (1993) 17: 49–51.
   Google Scholar
• SPALDING BJ: Analysts assess biopharmaceutical firms. Bio/technology (1993) 11: 986–987.
   Google Scholar
• McCORMICK DK: Solitaire. Bio/technology (1993) 11:419.
   Google Scholar